Piper Jaffray Upgrades BioCryst Pharma (BCRX) to Overweight

August 12, 2016 6:25 AM EDT
Get Alerts BCRX Hot Sheet
Price: $5.95 --0%

Rating Summary:
    12 Buy, 3 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade BCRX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Piper Jaffray upgraded BioCryst Pharma (NASDAQ: BCRX) from Neutral to Overweight with a price target of $8.00 (from $5.00) after the company dosed the first patient in its APeX-1 trial of '7353.

Analyst Charles C. Duncan commented, "On Thursday Biocryst dosed the first patient in its APeX-1 trial of '7353 and we’re upgrading shares from Neutral to Overweight as this program appears to be back on track and well-funded to produce the first meaningful Phase II results as early as YE16. We continue to believe that an oral candidate for HAE attack prevention can produce significant clinical value, and we’re encouraged Biocryst is now focused solely on 1x-daily ‘7353. We believe this second-gen candidate can overcome past formulation challenges to offer consistent, therapeutic kallikrein inhibition and are supportive of the APeX-1 trial design which appears well-vetted and risk-reduced compared to its past efforts. In advance of the APeX-1 Part 1 results ~YE16 to more fully characterize efficacy and safety of ‘7353, and to inform clean trial conduct in HAE attack prevention, we are moving to OW and increasing our PT from $5 to $8."

For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.

Shares of BioCryst Pharma closed at $5.03 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA, Hot Upgrades, Upgrades

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment